Medical Researches
Possibly Effective
Based on 32 Researches
DHA shows promise for psoriasisEffects of dietary supplementation with polyunsaturated ethyl ester lipids (Angiosan) in patients with psoriasis and psoriatic arthritis.
Combination treatment complicates evaluation
We evaluated the impact of docosahexaenoic acid (DHA) supplementation, alongside eicosapentaenoic acid (EPA), in patients suffering from chronic, stable psoriasis. This study involved 80 participants, 34 of whom also had psoriatic arthritis, and they were given specific doses of fatty acid ethyl esters for a period of eight weeks.
The results showed a noteworthy decrease in the Psoriasis Area Severity Index (PASI) scores, which went from an average of 3.56 before treatment to 1.24 after eight weeks. This significant reduction illustrates the potential effectiveness of DHA for managing symptoms of psoriasis, such as itching and plaque scaling.
It was particularly encouraging to see that seven patients were completely healed, with many others experiencing significant improvement. The majority of those with psoriatic arthritis reported feeling less joint pain during the study. Through our observations, it became clear that polyunsaturated ethyl ester lipids, like DHA, may serve as a valuable complement to traditional therapies for both psoriasis and psoriatic arthritis.
Read More
We aimed to understand how docosahexaenoic acid (DHA), one of the omega-3 fatty acids, affects psoriasis, particularly looking at its anti-inflammatory properties. The research focused on a mouse model designed to replicate psoriasis-like skin conditions. Over a 12-week period, we compared the effects of diets rich in either DHA or eicosapentaenoic acid (EPA) on skin inflammation and related lipid issues.
Our findings revealed that DHA treatment led to significant improvements. We noted a decrease in pro-inflammatory cytokines and bioactive lipid mediators circulating in the body. Moreover, DHA resulted in the skin showing higher levels of specific molecules like resolvin D5 and protectin DX, which help with resolving inflammation. On the other hand, while EPA also had some beneficial effects, they were not as pronounced as those from DHA, particularly in reducing harmful skin compounds.
Overall, our results suggest that DHA might be the more effective option when considering dietary interventions for managing psoriasis. This enhances our understanding of how omega-3 fatty acids can contribute positively to inflammatory skin conditions.
Read More
DHA improves psoriatic skin symptomsBiological action of docosahexaenoic acid in a 3D tissue-engineered psoriatic skin model: Focus on the PPAR signaling pathway.
Study focuses on DHA's effects
We explored the role of docosahexaenoic acid (DHA) in treating psoriasis using a 3D tissue-engineered skin model. Our goal was to understand how DHA might influence the symptoms of psoriasis, particularly through its impact on skin cell behavior and inflammation.
In the study, we created skin substitutes that mimic both healthy and psoriatic skin, adding 10 μM of DHA to the culture media. What we found was quite promising; the presence of DHA helped improve the abnormal cell behavior seen in psoriatic skin. Specifically, we observed increased expression of important skin proteins, like filaggrin and keratin 10, which are crucial for healthy skin function.
Additionally, DHA was integrated into the skin cell membranes and converted into another beneficial fatty acid, eicosapentaenoic acid (EPA). Notably, we saw a reduction in harmful inflammatory substances derived from other fatty acids, including prostaglandin E (PGE) and 12-hydroxyeicosatetraenoic acid (12-HETE).
Furthermore, DHA supplementation appeared to rebalance the expression of important receptors involved in cellular signaling and reduced the secretion of the inflammatory cytokine TNF-α. Overall, our findings suggest that DHA can help ease the symptoms of psoriasis by promoting healthier skin cell activity and curbing inflammation.
Read More
Rapid improvement in psoriasisA double-blind, randomized, placebo-controlled trial of n-3 fatty acid based lipid infusion in acute, extended guttate psoriasis. Rapid improvement of clinical manifestations and changes in neutrophil leukotriene profile.
Strong relevance to treated condition
We explored the effectiveness of a specialized treatment regimen involving docosahexaenoic acid (DHA) as part of an n-3 fatty acid lipid infusion for patients suffering from acute guttate psoriasis. This study included twenty hospitalized individuals with significant skin involvement and was conducted in a randomized, double-blind, placebo-controlled manner to ensure reliable results.
Participants received either a daily infusion of the n-3 fatty acid emulsion, which contained DHA and eicosapentaenoic acid (EPA), or a conventional n-6 lipid emulsion lacking significant benefits from omega-3s. We recorded clinical changes over ten days, assessing factors such as skin redness, swelling, and peeling, along with patients' subjective feelings about their symptoms.
The results were telling: those receiving the n-3 infusion showed a remarkable improvement in their psoriasis symptoms—between 45% and 76%—within just ten days. In contrast, the n-6 group experienced only moderate improvement, around 16-25%. Furthermore, we noted significant changes in the patients' immune response. The n-3 group had an increased production of beneficial leukotriene products, while inflammatory markers decreased, suggesting a positive modulation of the body's inflammatory response by DHA and EPA.
Overall, our investigation highlights a potential rapid benefit of using n-3 fatty acids, particularly DHA, in treating acute psoriasis. This indicates a promising avenue for improving the lives of those affected by this challenging skin condition.
Read More
We explored how docosahexaenoic acid (DHA)—a key component of fish oil—could have a positive impact on psoriasis, a skin condition known for its inflammation and excessive skin cell growth. The study focused on how DHA is metabolized in guinea pig skin and its potential to influence inflammatory processes associated with this condition.
During our research, we incubated guinea pig skin enzyme preparations with two types of fatty acids from fish oil, namely eicosapentaenoic acid and DHA. We found that these fatty acids get converted into specific metabolites that might help regulate unwanted inflammation. Notably, the metabolites 15-hydroxyeicosapentaenoic acid and 17-hydroxydocosahexaenoic acid emerged from this conversion and showed promise as inhibitors of an enzyme linked to the production of inflammatory compounds.
The findings indicated that these metabolites effectively inhibit the enzyme 5-lipoxygenase, which is responsible for producing LTB4—a molecule linked to the worsening of psoriasis. The inhibitory effects observed give us insight into a possible mechanism through which DHA from fish oil could help alleviate symptoms of this challenging skin disorder. This metabolic pathway opens up avenues for future research into the therapeutic potential of DHA for managing psoriasis and similar inflammatory conditions.
Read More